PARP and PI3K inhibition in pancreatic cancer: intravital insights and ‘fine-tune’ priming using AKT and single/double-strand DNA break biosensor mice. [ 2018 - 2020 ]

Research Grant

Researchers: Dr Paul Timpson (Principal investigator) ,  Dr Jennifer Morton ,  Dr Marina Pajic

Brief description Inefficient drug response in solid tumour tissue is often a limiting factor in the clinical effectiveness of cancer therapies. Using cutting-edge imaging technology and 3D models that mimic the disease, we can map areas of poor drug response within distinct regions of tumours with chemotherapy. Here, we will shift factors limiting efficient drug targeting in these areas to improve the encouraging anti-cancer profile of PI3K and DNA repair inhibitors in pancreatic cancer.

Funding Amount $AUD 760,505.07

Funding Scheme Project Grants

Notes Standard Project Grant